Quantbot Technologies LP Acquires New Stake in Medpace Holdings, Inc. $MEDP

Quantbot Technologies LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,297 shares of the company’s stock, valued at approximately $687,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Johnson Financial Group Inc. purchased a new stake in shares of Medpace during the second quarter valued at $27,000. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC bought a new stake in Medpace during the 4th quarter valued at about $30,000. Allied Private Wealth LLC bought a new stake in Medpace during the 2nd quarter valued at about $31,000. Finally, Kilter Group LLC purchased a new stake in Medpace in the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on MEDP. Truist Financial upped their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Mizuho lifted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday, July 23rd. Finally, Barclays set a $600.00 price objective on Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $584.18.

Insiders Place Their Bets

In other news, CFO Kevin M. Brady sold 3,400 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the sale, the chief financial officer owned 12,830 shares in the company, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the transaction, the director owned 27,825 shares in the company, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 129,963 shares of company stock valued at $79,364,624. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Performance

NASDAQ MEDP opened at $611.57 on Friday. The company has a market cap of $17.07 billion, a PE ratio of 35.85, a P/E/G ratio of 2.76 and a beta of 1.15. The firm’s 50 day moving average price is $562.52 and its 200-day moving average price is $493.80. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.